![]() This is due to its biocompatibility, good stability, easy fabrication and low cost. Eudragit RLPO is water insoluble polymer which is widely used as a wall material for controlled release microparticles. In the present investigation Eudragit RLPO is used as a rate retardant polymer. Among the various methods developed for formulation of microparticles, solvent evaporation method is one of the mostly widely used one to formulate Microparticles because of its ease of fabrication without compromising the activity of drug. Microencapsulation is a well-known method for the preparation of microparticles for controlled release. Therefore, development of controlled release dosage forms would clearly be beneficial in terms of decreased dosage requirements, thus increase patient compliance. ![]() ![]() This leads fluctuations in plasma concentration and also causes inconvenience to the patient. Due to its low biological half-life, it requires frequent administration to maintain plasma concentration. Studies with single oral doses in normal subjects and with multiple oral doses in patients with type II diabetes have shown significant absorption of Glimepiride within 1 hour after administration and peak drug levels (Cmax) at 2 to 3 hours. After oral administration, Glimepiride is completely (100%) absorbed from the GI tract. Glimepiride (Sahoo 2005) is the only third generation sulphonyl urea, which lowers the blood glucose level in the healthy subjects as well as in patients with type II diabetes. Formulation and evaluation of microencapsulated Glimepiride produced by the emulsion - solvent evaporation method. ![]() Eudragit RLPO microparticles containing Glimepiride could be prepared successfully by using an emulsion solvent evaporation technique, which will not only sustain the release of drug but also manage complicacy of the diabetes in a better manner. The mean particle size of microparticles ranges from 140.40 - 173.90 μm and encapsulation efficiency ranges from 90.46 – 93.09%. The resulting microparticles obtained by solvent evaporation method were free flowinging nature. Microparticles were prepared using Eudragit RLPO by emulsion solvent evaporation and characterized for their micromeritic properties, encapsulation efficiency, particle size, In vitro release studies were performed in phosphate buffer (pH 7.4). "The objective of the present investigation was to formulate and evaluate microencapsulated Glimepiride produced by the emulsion - solvent evaporation method. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |